Vericel Corporation (NASDAQ:VCEL), a specialized company in advanced therapies for sports medicine and severe burn care, has announced its upcoming participation in a fireside chat at the Truist Securities MedTech Conference. The presentation is scheduled for Tuesday, June 17, 2025, at 9:20 a.m. ET. Investors and interested parties can access the webcast through the Investor Relations section of Vericel's website at investors.vcel.com. This conference appearance provides an opportunity for investors to gain insights into Vericel's operations and strategic direction in the medical technology sector.
Vericel Corporation (NASDAQ:VCEL), un'azienda specializzata in terapie avanzate per la medicina sportiva e la cura delle ustioni gravi, ha annunciato la sua prossima partecipazione a una conversazione informale durante la Truist Securities MedTech Conference. La presentazione è prevista per martedì 17 giugno 2025 alle 9:20 ET. Investitori e interessati potranno seguire la diretta streaming nella sezione Investor Relations del sito di Vericel all'indirizzo investors.vcel.com. Questa partecipazione alla conferenza rappresenta un'opportunità per gli investitori di approfondire le operazioni e la direzione strategica di Vericel nel settore della tecnologia medica.
Vericel Corporation (NASDAQ:VCEL), una empresa especializada en terapias avanzadas para medicina deportiva y cuidado de quemaduras graves, ha anunciado su próxima participación en una charla informal en la Truist Securities MedTech Conference. La presentación está programada para el martes 17 de junio de 2025 a las 9:20 a.m. ET. Los inversores y partes interesadas pueden acceder a la transmisión en vivo a través de la sección de Relaciones con Inversores en el sitio web de Vericel en investors.vcel.com. Esta participación en la conferencia ofrece una oportunidad para que los inversores conozcan mejor las operaciones y la dirección estratégica de Vericel en el sector de tecnología médica.
Vericel Corporation(NASDAQ:VCEL)는 스포츠 의학 및 중증 화상 치료를 위한 첨단 치료 전문 기업으로, Truist Securities MedTech Conference에서 진행되는 파이어사이드 채팅에 곧 참여할 예정임을 발표했습니다. 발표는 2025년 6월 17일 화요일 오전 9시 20분(동부 시간)에 예정되어 있습니다. 투자자 및 관심 있는 분들은 Vericel 웹사이트의 투자자 관계 섹션 investors.vcel.com을 통해 웹캐스트에 접속할 수 있습니다. 이번 컨퍼런스 참여는 투자자들이 Vericel의 운영 현황과 의료기술 분야에서의 전략 방향에 대해 깊이 있는 정보를 얻을 수 있는 기회를 제공합니다.
Vericel Corporation (NASDAQ:VCEL), une entreprise spécialisée dans les thérapies avancées pour la médecine sportive et le traitement des brûlures graves, a annoncé sa prochaine participation à une discussion informelle lors de la Truist Securities MedTech Conference. La présentation est prévue pour le mardi 17 juin 2025 à 9h20 (heure de l'Est). Les investisseurs et les parties intéressées pourront accéder à la diffusion en direct via la section Relations Investisseurs du site web de Vericel à l'adresse investors.vcel.com. Cette participation à la conférence offre aux investisseurs une occasion d'obtenir des informations sur les opérations et la stratégie de Vericel dans le secteur des technologies médicales.
Die Vericel Corporation (NASDAQ:VCEL), ein auf fortschrittliche Therapien im Bereich Sportmedizin und schwerer Brandbehandlung spezialisiertes Unternehmen, hat ihre bevorstehende Teilnahme an einem Fireside-Chat auf der Truist Securities MedTech Conference angekündigt. Die Präsentation ist für Dienstag, den 17. Juni 2025, um 9:20 Uhr ET geplant. Investoren und Interessierte können den Webcast über den Bereich Investor Relations auf der Website von Vericel unter investors.vcel.com verfolgen. Diese Konferenzteilnahme bietet Investoren die Möglichkeit, Einblicke in die Geschäftstätigkeit und strategische Ausrichtung von Vericel im Bereich Medizintechnik zu erhalten.
Positive
None.
Negative
None.
CAMBRIDGE, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will participate in a fireside chat at the Truist Securities MedTech Conference at 9:20 a.m. ET on Tuesday, June 17 2025.
A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com.
About Vericel Corporation
Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel also holds an exclusive license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness burns. For more information, please visit www.vcel.com.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, to receive support.
